Psych Vivas · Foundations — basic neuroscience for psychiatry
Basic neuroscience for psychiatry — structured clinical viva
Fellowship viva on psychosis and depression neuroscience, methods limits, patient communication, and landmark models.
On this page
Study tools
Target exams
Interpretation
Reveal interpretationShowHide
Multilevel answer. Genes, development, substance hits, and stress can converge on synaptic and circuit dysfunction expressed as a clinical syndrome — not a single litre of wrong chemical. [1][5]
Psychosis model. Dopamine hypothesis version III: final common pathway of striatal dopamine dysregulation and aberrant salience; imaging supports increased dopaminergic occupancy/tone in samples. Cannabis is an upstream risk, not proof of one mechanism alone. [1][2]
Pathways. Teach mesolimbic (positive symptoms), mesocortical (cognition/negatives), nigrostriatal (EPS), tuberoinfundibular (prolactin). [1]
Scans. MRI if red flags; normal MRI does not exclude primary psychosis. fMRI BOLD is research haemodynamics, not a diagnostic photo of 'the imbalance.' [6] EEG if seizure/encephalopathy concerns.
Ketamine dual lesson. Psychotomimetic NMDA antagonism supports glutamate models; separate literature shows rapid antidepressant effects in treatment-resistant depression protocols — different clinical contexts. [3][4]
Depression contrast. Multilevel circuit and molecular dysfunction, stress–neurotrophic themes; reject pure serotonin deficiency monologue. [5]
Communication. 'Brain systems involved in meaning, motivation and perception are disrupted; medicines that modulate dopamine can reduce positive symptoms; recovery also needs psychosocial care; we do not diagnose this with a routine colour brain scan.' [1][6]
References6ShowHide
- [1]Howes OD, Kapur S The dopamine hypothesis of schizophrenia: version III--the final common pathway Schizophr Bull, 2009.PMID 19325164
- [2]Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia Proc Natl Acad Sci U S A, 2000.PMID 10884434
- [3]Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry, 1994.PMID 8122957
- [4]Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry, 2006.PMID 16894061
- [5]Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression Neuron, 2002.PMID 11931738
- [6]Logothetis NK, Pauls J, Augath M, et al. Neurophysiological investigation of the basis of the fMRI signal Nature, 2001.PMID 11449264